# Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Source: https://onco.cc/trials/nct05605535/  
OnCo record `nct05605535` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Oregovomab, Paclitaxel / nab-paclitaxel, Carboplatin in ovarian cancer, run by CanariaBio Inc., active and no longer recruiting.

## Summary

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer is a phase 2 interventional study registered as NCT05605535 by CanariaBio Inc., with 88 participants planned, started 2023-02-07 and due to reach its primary completion in 2026-10-15. Interventions recorded: Oregovomab, Paclitaxel, Carboplatin, Placebo. Conditions listed: Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05605535
- Phase: 2
- Setting: A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab) Versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
- Sponsor: CanariaBio Inc.
- Enrolled: 88

## Sources

- ClinicalTrials.gov NCT05605535: https://clinicaltrials.gov/study/NCT05605535

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Oregovomab](https://onco.cc/drugs/oregovomab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)

---
JSON: https://onco.cc/api/v1/entities/nct05605535.json